Oppenheimer set a $170.00 price target on SAGE Therapeutics (NASDAQ:SAGE) in a research report sent to investors on Monday, October 29th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
SAGE has been the subject of a number of other reports. Canaccord Genuity set a $220.00 price objective on shares of SAGE Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 8th. Morgan Stanley upped their price objective on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the stock an overweight rating in a research report on Thursday, October 11th. BidaskClub upgraded shares of SAGE Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, August 30th. Piper Jaffray Companies initiated coverage on shares of SAGE Therapeutics in a report on Monday, August 6th. They set an overweight rating and a $206.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on shares of SAGE Therapeutics from $198.00 to $239.00 and gave the stock a buy rating in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $204.14.
Shares of NASDAQ:SAGE traded up $1.04 during midday trading on Monday, hitting $108.43. The stock had a trading volume of 186,397 shares, compared to its average volume of 522,433. The stock has a market capitalization of $5.04 billion, a PE ratio of -15.29 and a beta of 2.76. SAGE Therapeutics has a fifty-two week low of $88.03 and a fifty-two week high of $195.97.
SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing the consensus estimate of ($2.41) by ($0.22). During the same quarter in the prior year, the business posted ($1.97) EPS. On average, sell-side analysts forecast that SAGE Therapeutics will post -7.58 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of SAGE. Franklin Resources Inc. grew its holdings in SAGE Therapeutics by 66.3% during the 3rd quarter. Franklin Resources Inc. now owns 950,773 shares of the biopharmaceutical company’s stock worth $134,277,000 after acquiring an additional 379,121 shares during the last quarter. Millennium Management LLC grew its holdings in SAGE Therapeutics by 622.4% during the 2nd quarter. Millennium Management LLC now owns 379,904 shares of the biopharmaceutical company’s stock worth $59,466,000 after acquiring an additional 327,312 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of SAGE Therapeutics by 789.3% in the 2nd quarter. Fiera Capital Corp now owns 273,918 shares of the biopharmaceutical company’s stock valued at $42,876,000 after purchasing an additional 243,118 shares during the last quarter. Waddell & Reed Financial Inc. bought a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at $34,640,000. Finally, American Century Companies Inc. boosted its stake in shares of SAGE Therapeutics by 63.6% in the 2nd quarter. American Century Companies Inc. now owns 527,062 shares of the biopharmaceutical company’s stock valued at $82,501,000 after purchasing an additional 204,831 shares during the last quarter.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Featured Article: The risks of owning bonds
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.